



(51) International Patent Classification:

Not classified

(21) International Application Number:

PCT/US2024/037846

(22) International Filing Date:

12 July 2024 (12.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/526,570 13 July 2023 (13.07.2023) US
63/605,695 04 December 2023 (04.12.2023) US

(71) Applicants: **INHIBRX BIOSCIENCES, INC.** [US/US];
11025 N.Torrey Pines Road, Suite 140, La Jolla, California
92037 (US). **PHYLAXIS BIOSCIENCE, LLC** [US/US];
100 Fillmore Street, #500, Denver, Colorado 80206 (US).

(72) Inventors: **BECKLUND, Bryan R.**; c/o Inhibrx Bio-
sciences, Inc., 11025 N.Torrey Pines Road, Suite 140, La
Jolla, California 92037 (US). **JONES, Kyle S.**; c/o Inhibrx
Biosciences, Inc., 11025 N.Torrey Pines Road, Suite 140,
La Jolla, California 92037 (US). **ECKLES, Andrew M.**;
c/o Inhibrx Biosciences, Inc., 11025 N.Torrey Pines Road,


Suite 140, La Jolla, California 92037 (US). **ECKELMAN,
Brendan P.**; c/o Inhibrx Biosciences, Inc., 11025 N.Tor-
rey Pines Road, Suite 140, La Jolla, California 92037 (US).
YAO, Tony Dung-Ling; c/o Phylaxis BioScience, LLC,
100 Fillmore Street, #500, Denver, Colorado 80206 (US).

(74) Agent: **XU, Lily** et al.; Goodwin Procter LLP, 100 Northern
Avenue, IP DOCKETING DEPT./7TH FL, Boston, Mass-
achusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: IGE BINDING PROTEINS AND USES THEREOF

**FIG. 1G**

(57) Abstract: Provided herein are IgE-binding VHH domains, polypeptides, and proteins, and methods of using such IgE-binding polypeptides and proteins to modulate the biological activity of IgE.

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*